Rein Therapeutics terminates Yorkville equity facility; $3M drawn, no penalties

Rein Therapeutics, Inc.

Terminated Pre-Paid Advance and Standby Equity Purchase Agreements with Yorkville on Dec 11, 2025.
Total $3M in advances drawn under PPA; most recent advance on Oct 23, 2025.
No sales of common stock executed under the Standby Equity Purchase Agreement.
No penalties or fees incurred in connection with the termination.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rein Therapeutics, Inc. terminated Standby Equity Purchase Agreement with YA II PN, Ltd. (effective 2025-12-11).

Action: termination
Agreement: equity purchase
Counterparty: YA II PN, Ltd.
Effective: 2025-12-11

Exact text from the filing

On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Standby Equity Purchase Agreement (the “SEPA”) dated July 29, 2025 also entered into with Yorkville.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rein Therapeutics, Inc. terminated Pre-Paid Advance Agreement with YA II PN, Ltd. (effective 2025-12-11).

Action: termination
Agreement: credit facility
Counterparty: YA II PN, Ltd.
Effective: 2025-12-11

Exact text from the filing

On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Standby Equity Purchase Agreement (the “SEPA”) dated July 29, 2025 also entered into with Yorkville.

View on SEC.gov

Browse all material agreements →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-316225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.